Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 14/20 | 0.69 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.48 |
| ▸ | GFER | P55789 | 2/20 | 0.48 |
| ▸ | CCNK | O75909 | 2/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.42 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | CDK7 | P50613 | 2/20 | 0.42 |
| ▸ | CCNH | P51946 | 2/20 | 0.42 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.42 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18697666 | 1.00 | HCRTR1 (0.69) | HCRTR1HCRTR2GFERCCNKCCNA2 | |
| SCHEMBL20144924 | 0.84 | HCRTR1 (0.69) | HCRTR1HCRTR2OPRK1 | |
| SCHEMBL16148240 | 0.82 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL16148238 | 0.82 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL20145121 | 0.81 | HCRTR1 (0.70) | HCRTR1HCRTR2 | |
| SCHEMBL20144890 | 0.81 | HCRTR1 (0.70) | HCRTR1HCRTR2 | |
| SCHEMBL17020864 | 0.78 | HCRTR1 (0.76) | HCRTR1HCRTR2 | |
| SCHEMBL20144833 | 0.77 | HCRTR1 (0.67) | HCRTR1HCRTR2 | |
| SCHEMBL20144926 | 0.77 | HCRTR1 (0.68) | HCRTR1HCRTR2 | |
| SCHEMBL20144885 | 0.76 | HCRTR1 (0.69) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970207-B1 | SUBSTITUTED PIPERIDINE COMPOUNDS AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-16 | — | — | EP | disclosed |